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Rapid developments in nano-technology are likely to confer significant benefits on mankind. But, as with
perhaps all new technologies, these benefits are likely to be accompanied by risks, perhaps by new risks.
Nano-toxicology is developing in parallel with nano-technology and seeks to define the hazards and risks
associated with nano-materials: only when risks have been identified they can be controlled. This article
discusses the reasons for concern about the potential effects on health of exposure to nano-materials and
relates these to the evidence of the effects on health of the ambient aerosol. A number of hypotheses are
proposed and the dangers of adopting unsubstantiated hypotheses are stressed. Nano-toxicology presents
many challenges and will need substantial financial support if it is to develop at a rate sufficient to cope with
developments in nano-technology.
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ano-technology has a strong claim to be re-
garded as the first important advance in tech-
nology of the third millennium. This is a
remarkable thought: who would care to predict what
other advances might occur during the coming thousand
years? Science fiction might be as good a guide as science
itself in predicting such developments; for those who
dream of space elevators constructed of woven graphene
produced on asteroids by self replicating machines, the
trilogy Red Mars, Green Mars and Blue Mars by Kim
Stanley Robinson is strongly recommended (1). Those
concerned about the possible effects on mankind of gene
therapy will also find this book interesting. But this is
science fiction, what of science fact? Well, even a slight
acquaintance with the nano-technology literature sug-
gests that the facts are fast approaching the predictions of
fiction. From the packaging of ‘smart drugs’ so that they
can reach the central nervous system or be directed
precisely towards tumour cells (2), to self cleaning
glass; from nano-silver being incorporated into odour-
eating socks to the development of stealth fighters; from
artificial muscles to desalination plants; from safer
nuclear power to better clinical diagnostics (3), there is
hardly a field of human endeavour in which nano-
technology has not been said to be likely to play
an important part. And the rate of development of the
field is staggering: well informed experts speak of a
trillion dollar industry appearing within just a few years
(4). The use of nano-materials seems to be likely to
become universal; little wonder, then, that concerns have
been expressed about the possible effects of exposure to
these materials. These include the very unlikely, ‘grey goo’
spreading across the land and the spread of self replicat-
ing, virus-simulating, nanobots, and the less unlikely
but by no means likely damage to health and to eco-
systems. The field is expanding in as many directions as
might well be imagined; nano-toxicology is one of these
directions. A Pub Med search on the word nanoparticle
produced more than 55,000 references: scanning the
list reveals many titles that might well have appeared
only a few years ago in science fiction. Nano-toxicology is
also developing rapidly and the funding base, though
weak only a few years ago is now strong though far from
what might be needed. Inhalation toxicology is experien-
cing a pleasurable renaissance: monographs are appear-
ing (46), new journals have been launched (Journal of
Nanotoxicology, Nanomedicine, Particle and Fibre Tox-
icology, Nature nanotechnology, Journal of Nanoparticle
Research, Nanotoxicology) and papers revealing the
effects or lack of effects of nano-particles are being
published almost daily. A number of wide ranging reviews
have been published (711). The 2005 review by
Oberdo ¨rster et al. (12) is outstanding and should be
studied by all interested in this field. Concern has
focused on engineered nano-particles. Comparatively
little attention has been focused on the potential hazards
of nano-particles used for medical diagnosis or on nano-
preparations of drugs: the likelihood of there being
general exposure to these preparations is, rightly, judged
to be low.
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Why so much concern? The fundamental reason is
simple: when materials are presented as nano-materials
they may behave physically, chemically and toxicologi-
cally in ways that cannot be predicted by study of the
parent material. Gold is an inert metal; nano-particles
of gold less than 10 nm in diameter burst into flames
on contact with oxygen. Even if less unexpected and
dramatic effects occur when nano-particles come into
contact with tissues the toxicological activities of materi-
als in nano-form may be quantitatively very different
from those of the parent materials. Titanium dioxide, the
standby negative control of many inhalation toxicolo-
gists, is much more active, in terms of producing an in-
flammatory response in the lung, when presented as 20 nm
diameter particles than as 250 nm diameter particles (12).
This very important finding has been disputed by
Warheit et al. (13): their paper should be studied for a
possible explanation (based on an examination of the
crystal structure of the materials used) for this discre-
pancy of findings. The worst case position is clear: any
material might be toxicologically active, or more active,
in an unpredictable way (quantitatively and more worry-
ingly, qualitatively) when presented to the body in nano-
form. Thus every material that might be presented to the
body, deliberately or accidentally, in nano-form needs to
be examined, in nano-form, for its toxicological effects.
Essentially: toxicologists can start again. In fact, the
worst case might be worse than this: not only should all
materials that might be presented in nano-form be
studied again but they should be studied when attached
to the surface of, or incorporated into, other materials
in nano-form. The interactions between the carried and
the carrier might define the toxicological properties of the
combination. And if that were not startling enough, the
same can be said for eco-toxicological effects.
A second reason for concern about the possible effects
on health of nano-particles lies in the air pollution field.
It is accepted that exposure to the ambient aerosol
damages health. This effect has been explored in terms
of the relationships between day to day variations in mass
concentrations of particles and daily counts of deaths,
hospital admissions and so on. In addition, long term
exposure to ambient particles monitored as PM2.5 (the
mass per cubic metre of particles generally less than 2.5
mm in diameter) has been shown to be associated with
increased risks of death from cardiovascular disease and
lung cancer. That deaths from cardiovascular disease
were associated with ambient particles was news in the
1990s and led Seaton and his colleagues to propose that
ultrafine particles might be the cause of this effect (14).
They argued that the mass dose of particles might be
misleading us (it is very small because ambient concen-
trations of particles are low, annual average PM2.5 in
England is of the order of 10 mg/m
3) and that very small
particles that contribute little to the mass but a great deal
to the number, of particles per unit volume of air, might
by crossing the alveolar air-tissue barrier triggering
effects that lead to a worsening of cardiovascular disease.
This was a startling idea: to some it suggested that the
wrong particles were being monitored; to others it
suggested a new field of research. Support for the idea
came from the work of Peters and colleagues (15) who
showed that blood viscosity in patients with CV disease
tracked with the number concentration of ambient
particles: See Delfino et al. (16), for further references
in this area. The possible prothrombotic effects of
nanoparticles have been explored by Geys et al. (17).
These authors showed that Quantum Dots could, at high
intravenous doses, induce pulmonary vascular thrombo-
sis in mice. Platelet aggregation and activation are
thought to underlie this effect. Seminal studies of nano-
particles by Oberdo ¨rster and his colleagues have provided
further support (1821). A surge of research on ambient
particles followed.
Possible explanations for the effects of ambient
particles
A number of theories to explain how ambient particles
might exert their effects have been put forward: the
generation of oxidative free radicals has proved a durable
suggestion; that transition metals might play a part in
this has received much support. It is interesting, in this
context, to note that Carbon Black appears to be able
to induce formation of oxidative free radicals without
the involvement of transition metals (22). It may be that
ultrafine particles act by delivering transition metals to
the alveolar surface, the metals then act as catalysts for
reactions that generate oxidative free radicals which can
damage cell membranes and trigger chain reactions. By
acting as catalysts and not as conventional reactants in
these reactions, transition metals might exert an effect far
beyond that which might have been predicted on the basis
of the mass dose of metals delivered to the lung. In fact
the mass dose of metals will, inevitably, be very small:
they make up only a fraction of the mass dose of the
particles and that dose is, itself, small. By triggering chain
reactions the metals might, again, cause effects out of
proportion to their mass. That the ultrafine particles
might cross into the blood and be disseminated to other
organs and there produce a wide range of effects, has
been suggested (see below). All too quickly the hypothesis
expanded towards explaining everything and has become
difficult to test. Diagrams showing the possible disper-
sion of inhaled, ingested or dermally absorbed nano-
articles throughout the body have become commonplace
in reviews of this subject (12). Such diagrams, inevitably
at this stage, lack information on the quantitative
importance of the various pathways indicated. What
percentage of inhaled particles crosses from the alveoli
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olfactory nerves? How are nano-particles excreted? Are
they sequestrated at sites in the body, for example in
the cells of the reticulo-endothelial system? What of
species differences? What of differences from one nano-
particle to another or, even, from one sample of one type
of nano-particle to another? Some of these questions are
discussed below.
Definitions
Nano-toxicology grew from studies of ultrafine particles.
It might be useful, now, to define ultrafine and nano-
particles. The term ‘ultrafine’ is used by many air pol-
lution scientists to denote particle of less than 100 nm
diameter. The term ‘nano-particle’ has rather overtaken
the term ‘ultrafine particle’ and is now used to describe
material presented in a form such that at least one
dimension of the unit material is of less than 100 nm.
Thus nano-dots, nano-spheres, nano-plates, nano-tubes,
nano-wires are all nano-materials or nano-particles.
Nano-tubes have attracted much attention. These gra-
phene structures may be single or multi-walled and may
carry contaminating metals (derived from the production
process) on their surfaces. They are notable strong and
are commonly many times longer than they are broad.
Tough, long, narrow fibres that are deposited in the
alveoli: new asbestos? Perhaps so: certainly the work of
Poland et al., Tagaki et al. and Mercer et al. (2325)
suggests that exposure to such materials should be
controlled.
The peculiar challenge of nano-toxicology
Toxicological testing of every material that might be
presented to the body, deliberately or accidentally, in
nano-form is infeasible; developing a capacity to predict
the effects of nano-materials is essential. On this most
toxicologists agree; developing the theory, a general
theory of nano-particle toxicology, is more difficult. But
a similar problem was faced more than thirty years ago
in the fibre-toxicology field and the characteristics of
fibres that should be causes for concern were defined.
These included the ratio of fibre length to breadth, the
durability of fibres in the lung and the level of exposure.
These have been found to be reliable guides. Developing
similar, albeit no doubt more complex, guides for
predicting the toxicological effects of nano-particles is
perhaps the key challenge of nano-toxicology.
All toxicologists would agree that defining the material
to be studied is important. Often this is not too difficult:
a study of the toxicology of potassium cyanide adminis-
tered intravenously would require that the purity of the
sample of salt was known. Complete purity is impossi-
ble but the very minor impurities in potassium cyanide
bought from a reputable supplier are unlikely to make
much difference to the results of the study. The level of
purity of the preparation used would, of course, be
reported. Consider, now, the problems of dealing with a
sample of carbon nano-tubes. These might be received
from the supplier in a bottle: the material would look
much like soot. The material is insoluble in water.
Determining the physical characteristics of the material
would be a challenge; a challenge far beyond the abilities
or, at least, the resources of most toxicologists. A group
of distinguished workers in the field have defined 17
physico-chemical characteristics which might be impor-
tant to determine before studying such material (26).
These include particle (in this case fibre) size, shape,
surface area per unit mass and also porosity, surface
contamination and surface charge in suspension and in
bio-fluid surrogates. Fubini et al. have stressed similar
features of nano-particles with an emphasis on possible
genotoxic effects (27). Rather worryingly the history of
the material is also important. This is avery real problem:
if the material changes with storage then the toxicologist
will have additional problems. Heraclitus said that one
could not step twice into the same river; Cratylus
famously capped this by saying that one could not step
once into the same river. The same might almost be said
of a sample of nano-material: we can discover something
of the specific material provided and studied the way
described, but can we use this information in a predictive
sense and develop from it our general theory?
Difficulties in characterising the material to be studied
become more taxing when we move away from the stock
bottle, though difficult enough there, to the animal. If
exposure by inhalation is intended then some means of
aerosolising the particles will be needed. At present there
are few devices that will produce a satisfactory aerosol
of carbon nano-tubes: one such device which has been
developed in the US is currently being built for the
National Nano-toxicology Research Centre at Chilton in
England. The aerosol may change in the period between
generation and inhalation: agglomeration (weak adhe-
sion between primary particles) or aggregation (firm
adhesion) may occur and, of course the aerosol will
have to be monitored. Monitoring the aerosol for
distribution of particle size is costly and requires a
familiarity with aerosol physics (28). Once inhaled the
aerosol may undergo further changes on coming into
contact with the lining fluid of the lung. Further
aggregation or, as some have suggested, disaggregation
may occur. The particles will hardly remain in their
original state: coating with lipids and proteins is likely,
perhaps inevitable. What the effects of such coatings may
be is unknown; perhaps they aid penetration into cells,
perhaps they increase the likelihood of uptake of particles
by macrophages. The effects of charge on the acquisition
of a coating and on the likelihood of the particles
crossing cell membranes require study.
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almost as demanding: anybody can add a gram or two of
nano-particles to saline, sonicate it and inject a sample
of the suspension into an animal. But determining the
state of the particles in the suspension is far from easy.
Aggregation is likely to occur and dispersants are
commonly used to prevent this. The toxicological effects
of these dispersants, not per se but in association with the
particles, require study (29). This is difficult as one might
not be able to study the effects of the particles without the
dispersant though one can study the dispersant without
the particles. And, of course, nano-particles cannot be
made visible with a conventional light microscope: the
limit of resolution (250 nm) prevents this. Instruments
that rely on light scattering do allow resolution of a sort:
rather as we see stars, as points of light rather than as
structures (for example the moon) with defined edges and
surface features. Labelling of nano-particles with fluor-
escent materials also allows them to be seen using a light
microscope. Electron microscopy, of course, allows nano-
particles to be seen but sampling of suspensions and
tissues containing nano-particles for EM study brings its
own problems.
Current work with radioactive nano-particles
These difficulties have led research workers to work with
simpler systems. One successful approach has involved
the production of nano-particles of Iridium 192 (
192Ir).
This radio-isotope is an emitter of beta and gamma
radiation with a half life of 74 days and can be monitored
in tissue. Nano-particles can be produced by generating a
high voltage spark across two iridium electrodes. Iridium
labelled carbon nano-particles can be produced by
substituting a carbon electrode for one of the iridium
electrodes. The primary particles produced are of about
4 nm diameter but these soon aggregate to produce larger
particles. The extent of aggregation can be controlled
by adjusting the flow of inert gas through the system.
Particles of 15 and 80 nm diameter have been used by
Kreyling et al. (30). Iridium is a hard metal, few if any are
harder, and effectively insoluble in body fluids even when
presented in nano-form. Presentation in this form pro-
vides a large surface area per unit mass and is stern test of
insolubility. What happens to these particles in the lung?
It has been shown that they are cleared rapidly from the
lung but, importantly, that they do not translocate
efficiently into the blood stream. Kreyling et al. report
less than about 1% of these particles pass to the blood
(30). Is this surprising? It is indeed surprising because it
has been thought that nano-particles pass easily across
the lung to the blood: their small size suggests that this
might occur (31). Rather oddly, this assumption is at odds
with the theory of filtration of particles: nano-particles
are rather well trapped by filters because of their rapid
diffusion onto the filter substrate. This, by the way,
explains the extensive trapping of nano-particles of less
than 10 nm diameter by the nose and pharynx. Whether
other nano-particles are also held back, rather effectively,
by the airblood barrier remains to be seen. Geiser et al.
have also reported that nano-particles are not very
effectively taken up by alveolar macrophages (32, 33). Is
this surprising? Perhaps not: macrophages are, so to
speak, in the business of clearing bacteria and cellular
debris from the alveolar surface; it is at least conceivable
that nano-particles are not ‘noticed’ by macrophages. Of
course if nano-particle aggregated in the lining fluid
of the alveoli the likelihood of uptake by macrophages
would be increased and there is some evidence that this
occurs (34, 35). Interaction between nano-particles and
the surfactant film that lies on the surface of the alveolar
cells has received some attention. Geiser et al. have
argued that the surfactant film ensures wetting of the
particles and is involved in moving the particles to the
aqueous hypophase (36). Damage to the surfactant film,
characterised by impairment of the capacity of the film to
expand, has also been reported (37). This is clearly, or
at least potentially, important: the increase in surface
tension of the surfactant film of expansion and its
decrease on contraction is essential for alveolar stability.
The low surface tension of the surfactant film is also
thought to be important for limiting transudation of fluid
from the interstitium to the alveolar surface. The limited
translocation of nano-particles to the blood is at odds
with the well established finding that nano-particles
translocate effectively to the interstitium of the lung
(38). It has been suggested that some secondary clearance
from the interstitium back to the airway surface occurs as
part of the process of clearing nano-particles from the
lung. The present author and colleagues have recently
hypothesised that nano-particles might well penetrate
into Type I alveolar cells, induce apoptosis of these cells
and then be cleared with the cellular debris by macro-
phages (39). Whether this will turn out to be true remains
to be seen.
Nano-particles and the brain
Nano-particles have been shown to enter the sensory cells
of the olfactory epithelium and to be transported via the
olfactory nerves to the olfactory lobes of the brain (40).
That they enter the nerve a terminal is surprising, that
they are transported via the axons to the brain is not.
Retrograde axonal transport is a well established process:
it explains the movement of the polio virus from skin
abrasions to the spinal cord. That nano-particles are
transported onwards along the olfactory pathways of the
brain is surprising. This implies that they can cross
synaptic junctions: how they do this is unknown. It will
be appreciated that such findings have the capacity to
induce a high level of concern: are the nano-particles of
the ambient aerosol, even now, penetrating to our brains?
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In discussing the possible effects of nano-particles we
should consider how these structures might act. Much
depends on whether the material is soluble or insoluble in
the tissues. If the nano-particles, or some components of
the nano-particles, are soluble then we may be dealing
with a delivery-system effect with the transported sub-
stance producing its own specific effects. This might well
be complicated: nano-particles might reach parts of the
body that are inaccessible to the soluble material and thus
cause unexpected effects. The possible delivery of metals
to the brain is an obvious example, especially if nano-
particles can cross the blood brain barrier. That some
nano-particles that are used for drug delivery can do
this has been established; that engineered nano-particles
and ambient nano-particles can do this is less clear.
One aspect of what might be called the ‘special delivery
hypothesis’ is the delivery of material to the interior of
cells. There is some evidence to show that nano-particles
can enter mitochondria: the possibility of activation of
apoptotic pathways has been suggested. Xia et al. have
examined the effects of ultrafine particles on mitochon-
drial function (41). In this work diesel ultrafine particles
were used and effects on the potential across the mi-
tochondrial membrane were found. This and other
effects were attributed to quinones and other organic
compounds associated with the particles. But we should
ask whether nano-particles locate preferentially to mito-
chondria in comparison, that is, with location in other
organelles and the inter-organelle matrix. This is un-
known. Work by Geiser and Kreyling has shown that
nano-particles appear to be distributed through the
tissues of the lung in accordance with the volume fraction
contributed by each type of tissue (42). This suggests a
random distribution and not preferential uptake by
specific cells. The need to extend this analysis to the
distribution within cells is clear. A second feature of the
‘special delivery hypothesis’ is the potentially high con-
centration of the leachate (the material that dissolves
from the nano-particles) at the site reached by the
particles. This might be important, whether it is or not
is unknown.
How insoluble nano-particles might damage
cells
If we turn to truly insoluble particles then we should
consider their effects in terms of their physical presence
and, also, in terms of their adsorptive properties.
The physical presence of particles within macrophages
affects macrophage function. This was shown long ago:
rat macrophages can become overloaded with particles
and cease to move. Oberdo ¨rster has reported that effects
on macrophage mobility begin when about 6% of the
volume of the cell is occupied by particles. Interestingly,
impairment of movement occurs at a lower percentage
occupancy (23%) when nano-particles are involved
(18,43). Why is this? One possible answer is that the key
factor that relates to interference with the functioning of
intracellular actin is total intracellular particle surface
area. Impairment of cell movement and function can lead
to necrotic changes in the cell: the process of frustrated
phagocytosis seen in macrophages that have bitten off, so
to speak, rather more of an asbestos fibre than they can
chew, provides an example. That frustrated phagocytosis
can occur when macrophages encounter long carbon
nano-tubes has been suggested by Poland et al. (23).
Adsorption of essential components in the extracellular
space might also occur. We have touched on possible
effects on surfactant; little seems to be known about
adsorption of intracellular substances. Adsorption of
extracellular substances might enhance the capacity of
nano-particles to cross cell membranes, it is possible that
the surface coating might then be removed, perhaps by
lysosomes, and the naked nano-particle exposed. If the
particle is active in its naked form we might be consider-
ing a ‘Trojan horse hypothesis’. The key word here is
hypothesis.
Human exposures to nano-particles
We are all exposed, continuously, to nano-particles of the
ambient aerosol. As one might expect, only a limited
number of volunteer studies have been done in this area.
Interestingly, Kuschner et al. have reported that exposure
to fine and ultrafine magnesium oxide particles produced
no signs of pulmonary inflammation as judged by
examination of lavage fluid (44). This is a potentially
important finding because it casts doubt on the theory
that the physical characteristics of the particles control
the response and suggests that the chemistry of the
particles is important. This study does not seem to have
been repeated or followed up.
Hazards and risks
That nano-particle might have toxicological effects is all
too clear; what is a great deal less clear is whether they are
having such effects now and whether, as a result of
exploitation of nano-technologies, they will have effects
or increased effects in the future. All toxicologists know
the difference between hazard and risk. Discussing these
terms again might seem otiose but perhaps this is not so.
Consider first the term hazard: the capacity to do harm.
Potassium cyanide is undoubtedly a hazard. But what is
the risk on exposure to 1ng of potassium cyanide? Most
toxicologists would say, none at all. So, if we accept that
there is a threshold of effect then at exposures below that
threshold potassium cyanide is not a hazard. At exposure
above the threshold it is and each exposure is associated
with some level of risk: risk being defined as the
probability of harm occurring as a result of exposure to
the hazard. This is one way of looking at the question;
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defined as a hazard but that at all doses below a certain
level the risk associated with the exposure is zero. The
standard paradigm of safety assessment of chemicals calls
for identification of hazard and then estimation of risk.
In the air pollution field this sequence has been reversed:
we have discovered the risk associated with exposure to
the ambient aerosol and are now struggling to identify
and explain the hazard that underlies the risk. As far as
we can tell, at a population level, there is no threshold of
effect for the effects of the ambient aerosol. The effects
with which we are concerned are, in general, not those
associated with effects on the genetic material of cells but
are effects on the cardiovascular and respiratory systems:
effects that are usually thought to be characterised
by thresholds of effect. Had any toxicologist been asked,
30 years ago, whether exposure to a few mg/m
3 of the
ambient aerosol would have effects on health he would
have replied in the negative. To those working in
toxicology and in air pollution science these findings
are, or should be, worrying. They show that we cannot
predict effects at a population level by toxicological
hazard assessment. With the aid of hind-sight this might
be explained by arguing that the range of genetic
polymorphisms that probably exist within the whole
population renders some people more susceptible to the
effects of the ambient aerosol than are others. Perhaps
so: but what does this tell us about the risks of
other materials, nano-materials, to which the whole
population might be exposed? It tells me that we should
be cautious.
Novel effects and unsupported hypotheses
In studying the toxicological effects of nano-materials we
may be faced with avery difficult problem: one is unlikely
to see that for which one does not look. Standard
toxicological techniques have been developed to look
for the effects of chemicals and the effects that are looked
for are those that are well described and, to some extent,
understood. How then should we react to the suggestion
that nano-materials might have unexpected toxicological
effects? Let us imagine that it were to be suggested that
exposure to nano-particles increased, to a modest extent,
the likelihood of development of Alzheimer’s disease.
Would we be able to predict this by means of a standard
toxicological screening battery? Do rats or other com-
monly used laboratory species develop Alzheimer’s dis-
ease? One would be unsurprised if the answers to both
questions were, no. A neuro-toxicologist would perhaps
argue that methods that do allow subtle effects on the
central nervous system to be detected have been devel-
oped. No doubt this may be so but including them in a
standard test battery would be costly. The parallel with
the air pollution field is clear: it would not have been
predicted that exposure to the ambient aerosol causes
accelerated thickening of the walls of the carotid arteries
of people. But we know that this occurs from epidemio-
logical studies in man (45). Standard screening batteries
do not look at arterial wall thickness; of course if the
changes were gross they might be noticed on histological
examination of tissue removed post-mortem, but modest
effects might well escape attention. This gets to the heart
of toxicology: if you give big doses to experimental
animals and don’t see effects, people should be safe, even
allowing for interspecies and intra-species differences in
sensitivity, at much lower levels of exposure. But this
assumes you know what you are looking for: some would
say that this was an unwise assumption in the context of
nano-toxicology. The danger here is that effects that
would go undetected in standard toxicological product-
screening can always be suggested. Whether these effects
are possible, let alone likely, is another question. Let us
imagine, for example, that I suggest that nano-particles
can enter the dendritic cells (cells that are key to antigen
presentation to lymphocytes) of the walls of the airways.
This is, in fact, not unlikely: these cells take up antigen.
Let me also suggest that the uptake of nano-particles
impairs the functioning of these cells. I have no idea
whether this is true: I have certainly never heard it
suggested. Would malfunctioning, perhaps rather minor
malfunctioning, of these cells be detected by standard
toxicological methods? Indeed not. Would malfunction-
ing of these cells affect the capacity of some people to
resist respiratory infections? It might. The danger is clear:
if the utterly unsupported, but not entirely implausible,
hypothesis is accepted then the deduction is not at all
unreasonable. That suggestions such as this will be made
as nano-technology expands and people are, perhaps,
exposed to a greater variety of nano-particles, is certain.
Deciding how to respond to such suggestions is part of
the challenge of nano-toxicology.
Exposure
We have considered hazard and risk and it seems certain
that some nano-particles constitute a hazard and, if expo-
sure occurs, might pose a risk to health. If? Yes, if ex-
posure occurs. How likely is exposure to nano-particles?
Exposure to the nano-particles of the ambient aerosol
is certain as long as people need to breathe. Exposure
to nano-materials developed for use in medical diagnostic
methods and in therapy will be limited to those requiring
such assistance. We might expect that Regulatory Autho-
rities concerned with the safety of drugs and medical
appliances will insist on rigorous testing of these pro-
ducts. In addition, any risk to patients should be
balanced against the benefits conferred by better diag-
nosis and therapy. More worrying are engineered nano-
particles which might be incorporated into a wide range
of products and encountered, essentially unwittingly,
by the public. Whether exposure to the nano-materials
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moot point. The tennis player grasping the handle of a
racket with a form of nano-carbon fibre bonded into its
structure is in contact with a nano-material bound into a
matrix. That he will inhale nano-fibres released from his
racket is very unlikely. But the person wearing odour-
eating socks might be in rather closer contact with nano-
particles of silver attached to the fibres of the sock. Will
these particles be absorbed via the skin? Will these
particles be released into the effluent from his washing
machine when he washes his socks? And, if so, will the
silver particles endanger invertebrates in the water course
to which the effluent runs? These questions remain to be
answered.
Exposure to nano-particles used in commercial pro-
ducts might occur at three main stages of the product
cycle. The first is in construction of the product:
occupational exposure of the workers making the pro-
duct. This is possible, indeed likely, unless precautions
are taken. Exposure could occur during the production
of the nano-material or during its incorporation into
final products. The problem here is one of occupational
hygiene and advice has been provided on this in the UK
by the Health and Safety Executive (46). Exposure dur-
ing product use is less likely but exposure as a result
of product disposal is possible and is a cause of some
concern. Materials containing nano-materials may be
disposed of to land-fill and as the products breakdown
nano-materials may be released to water courses. Burning
may also release nano-materials. Concerns about the
possible asbestos-like properties of nano-tubes have led
to advice that these materials should be treated as if they
were asbestos. This will impose strict requirements on
those dealing with the disposal of such materials.
Conclusions
Nano-technology is new and is expanding rapidly. As
with perhaps all new technologies benefits will be
conferred and risks will be encountered. Identifying the
risks to health before damage to health occurs is the
taskof the nano-toxicologist. This is by no means an easy
task: as yet we are unlikely to know about all the risks
for which we should be looking. Research is needed.
Industry might reasonably be required to take charge of
investigating the safety (or danger) of their products but
an extensive programme of basic research is needed to
identify possible risks and to work out the mechanisms
by which nano-materials might affect the body.
Such research requires funding from government: it is
encouraging to know that in the UK such funding is
being provided and that a National Nano-toxicology
Research Centre has been established by the Health
Protection Agency. Will this be enough? I suspect not.
Nano-technology runs the risk of becoming a perfect
‘scare story’ for the media and public confidence could
easily be lost. One has only to look at the furore over GM
crops to see what might happen.
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